$CDNA
CareDx, Inc.

2016 Q3 Form 10-Q Financial Statement

#000156459016029303 Filed on November 14, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q3
Revenue $12.48M $7.151M
YoY Change 74.45% 7.47%
Cost Of Revenue $2.604M $2.568M
YoY Change 1.4% 44.92%
Gross Profit $9.871M $4.583M
YoY Change 115.38% -6.12%
Gross Profit Margin 79.13% 64.09%
Selling, General & Admin $8.630M $5.423M
YoY Change 59.14% 45.43%
% of Gross Profit 87.43% 118.33%
Research & Development $2.930M $2.698M
YoY Change 8.6% 160.42%
% of Gross Profit 29.68% 58.87%
Depreciation & Amortization $1.100M $220.0K
YoY Change 400.0% 69.23%
% of Gross Profit 11.14% 4.8%
Operating Expenses $11.45M $10.34M
YoY Change 10.69% 96.62%
Operating Profit -$1.579M -$3.193M
YoY Change -50.55% -329.22%
Interest Expense $568.0K $251.0K
YoY Change 126.29% -146.48%
% of Operating Profit
Other Income/Expense, Net -$130.0K -$45.00K
YoY Change 188.89% -112.68%
Pretax Income -$4.248M -$3.489M
YoY Change 21.75% -387.63%
Income Tax -$449.0K $0.00
% Of Pretax Income
Net Earnings -$3.764M -$3.489M
YoY Change 7.88% -387.63%
Net Earnings / Revenue -30.17% -48.79%
Basic Earnings Per Share -$0.20 -$0.29
Diluted Earnings Per Share -$0.26 -$0.29
COMMON SHARES
Basic Shares Outstanding 19.10M 11.89M
Diluted Shares Outstanding 19.48M 11.89M

Balance Sheet

Concept 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.30M $34.00M
YoY Change -34.41% -12.82%
Cash & Equivalents $22.27M $33.95M
Short-Term Investments
Other Short-Term Assets $800.0K $1.000M
YoY Change -20.0% 42.86%
Inventory $7.444M $814.0K
Prepaid Expenses
Receivables $4.600M $2.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $35.12M $37.97M
YoY Change -7.5% -9.62%
LONG-TERM ASSETS
Property, Plant & Equipment $3.305M $2.571M
YoY Change 28.55% 25.48%
Goodwill $28.05M $12.01M
YoY Change 133.63% 0.0%
Intangibles $35.44M $6.650M
YoY Change 432.99% 0.0%
Long-Term Investments
YoY Change
Other Assets $30.00K $0.00
YoY Change
Total Long-Term Assets $66.97M $21.37M
YoY Change 213.33% 2.5%
TOTAL ASSETS
Total Short-Term Assets $35.12M $37.97M
Total Long-Term Assets $66.97M $21.37M
Total Assets $102.1M $59.34M
YoY Change 72.04% -5.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.464M $1.949M
YoY Change 77.73% 88.13%
Accrued Expenses $12.20M $4.800M
YoY Change 154.17% 84.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $17.90M $3.594M
YoY Change 398.11% -38.01%
Total Short-Term Liabilities $39.61M $10.45M
YoY Change 278.85% -5.97%
LONG-TERM LIABILITIES
Long-Term Debt $8.496M $12.13M
YoY Change -29.93% 74.96%
Other Long-Term Liabilities $10.30M $28.00K
YoY Change 36685.71% -99.26%
Total Long-Term Liabilities $8.496M $12.15M
YoY Change -30.09% 75.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.61M $10.45M
Total Long-Term Liabilities $8.496M $12.15M
Total Liabilities $48.10M $25.44M
YoY Change 89.08% 16.57%
SHAREHOLDERS EQUITY
Retained Earnings -$168.3M
YoY Change 5.62%
Common Stock $12.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.20M $33.90M
YoY Change
Total Liabilities & Shareholders Equity $102.1M $59.34M
YoY Change 72.05% -5.6%

Cashflow Statement

Concept 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$3.764M -$3.489M
YoY Change 7.88% -387.63%
Depreciation, Depletion And Amortization $1.100M $220.0K
YoY Change 400.0% 69.23%
Cash From Operating Activities -$1.200M -$3.030M
YoY Change -60.4% -17.21%
INVESTING ACTIVITIES
Capital Expenditures -$350.0K -$390.0K
YoY Change -10.26% 129.41%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$350.0K -$390.0K
YoY Change -10.26% 95.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.680M 480.0K
YoY Change 1291.67% -98.63%
NET CHANGE
Cash From Operating Activities -1.200M -3.030M
Cash From Investing Activities -350.0K -390.0K
Cash From Financing Activities 6.680M 480.0K
Net Change In Cash 5.130M -2.940M
YoY Change -274.49% -109.43%
FREE CASH FLOW
Cash From Operating Activities -$1.200M -$3.030M
Capital Expenditures -$350.0K -$390.0K
Free Cash Flow -$850.0K -$2.640M
YoY Change -67.8% -24.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8496000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21277644
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29888000
CY2016Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
4568000
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2367000
CY2015Q4 us-gaap Inventory Net
InventoryNet
766000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1341000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
34362000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2425000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6650000
CY2015Q4 us-gaap Goodwill
Goodwill
12005000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
147000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
242000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
142000
CY2016Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6896000
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202564000
CY2015Q4 us-gaap Minority Interest
MinorityInterest
0
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29494000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55638000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11902346
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11902346
us-gaap License And Services Revenue
LicenseAndServicesRevenue
226000
us-gaap Interest Expense
InterestExpense
1334000
CY2016Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
133000
CY2015Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
45000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3334000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
142000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22265000
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
143000
CY2016Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
310000
CY2016Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
17902000
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
CDNA
dei Entity Registrant Name
EntityRegistrantName
CareDx, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001217234
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap License And Services Revenue
LicenseAndServicesRevenue
349000
CY2015Q4 us-gaap Assets
Assets
55638000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10152000
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2892000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1644000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3725000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2366000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2866000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1426000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
703000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
21147000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
7228000
CY2016Q3 cdna Business Acquisition Deferred Payment Consideration With Interest Accretion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretion
5942000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3464000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39605000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2015Q4 us-gaap Liabilities
Liabilities
26144000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173082000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
29494000
CY2016Q3 us-gaap Goodwill
Goodwill
28047000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2016Q3 us-gaap Assets
Assets
102092000
CY2016Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
35444000
CY2016Q3 us-gaap Inventory Net
InventoryNet
7444000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3305000
CY2016Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8204000
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
846000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
58000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
35123000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8553000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6453000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6629000
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6736000
CY2016Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
8613000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1190000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
744000
CY2016Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
526000
CY2015Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
7007000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
22317000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3193000
us-gaap Operating Expenses
OperatingExpenses
48242000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18471000
CY2016Q3 us-gaap Interest Expense
InterestExpense
568000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24935000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3754000
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
108000
CY2015Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
144000
CY2016Q3 us-gaap Revenues
Revenues
12475000
CY2015Q3 us-gaap Revenues
Revenues
7151000
us-gaap Revenues
Revenues
29771000
CY2016Q3 us-gaap Cost Of Services
CostOfServices
2604000
CY2015Q3 us-gaap Cost Of Services
CostOfServices
2568000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
3355000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q3 us-gaap Interest Expense
InterestExpense
251000
us-gaap Interest Expense
InterestExpense
1351000
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1386000
CY2015Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1779000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4248000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3489000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-449000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-888000
us-gaap Profit Loss
ProfitLoss
-24047000
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-35000
CY2015Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19481424
us-gaap Net Income Loss
NetIncomeLoss
-23989000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-3799000
CY2015Q3 us-gaap Profit Loss
ProfitLoss
-3489000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-58000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3764000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3489000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19098626
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11890057
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14894218
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11890057
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14894218
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-423000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1831000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4222000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3489000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25878000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-35000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-58000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4187000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3489000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25820000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2195000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
575000
us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
2738000
us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
0
us-gaap Share Based Compensation
ShareBasedCompensation
1511000
us-gaap Share Based Compensation
ShareBasedCompensation
1028000
cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
43000
cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
115000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
354000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
690000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-446000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-325000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
129000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
393000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-990000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
791000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
824000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
508000
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
68000
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
11000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2593000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
947000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5776000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
627000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1123000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
20567000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-21194000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1123000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1290000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13462000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
15625000
cdna Proceeds From Issuance Of Common Stock Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost
8293000
cdna Proceeds From Issuance Of Common Stock Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
20625000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
304000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
2170000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
27061000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4422000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-28000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7623000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2477000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36431000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33954000
cdna Common Stock Issuance Costs Accrued Not Paid
CommonStockIssuanceCostsAccruedNotPaid
461000
cdna Common Stock Issuance Costs Accrued Not Paid
CommonStockIssuanceCostsAccruedNotPaid
0
CY2016Q3 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
5700000
CY2015Q3 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
0
cdna Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
13421000
cdna Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
0
cdna Common Shares Issued As Part Of Acquisition
CommonSharesIssuedAsPartOfAcquisition
7205000
cdna Common Shares Issued As Part Of Acquisition
CommonSharesIssuedAsPartOfAcquisition
0
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i)&#160;revenue recognition, (ii)&#160;the differences between amounts billed and estimated receipts from payers, (iii)&#160;the determination of the accruals for clinical studies, (iv)&#160;the determination of refunds to be requested by third-party payers, (v)&#160;the fair value of assets and liabilities, (vi)&#160;inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii)&#160;the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi)&#160;the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii)&#160;any impairment of long-lived assets, including in-process technology and goodwill, and (xiii)&#160;legal contingencies. Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company&#8217;s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. As of September 30, 2016, these financial instruments were held in Company accounts at eight financial institutions. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located primarily in the U.S. and billed to various third-party payers, and sales of Olerup SSP products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., and Latin America and other. <font style="color:#000000;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. </font>For the nine months ended September 30, 2016 and 2015, approximately 45% and 50%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. Product revenue accounted for 30% and 24% of total revenue for the three and nine months ended September 30, 2016, respectively. At September 30, 2016, Medicare accounted for approximately 20% of accounts receivable. At December&#160;31, 2015, Medicare and Aetna accounted for approximately 35% and 21% of accounts receivable, respectively. No other payers or customers represented more than 10% of accounts receivable at either September 30, 2016 or December&#160;31, 2015. </p></div>
us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration, License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has generated revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company&#8217;s performance obligations under its collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the three and nine months ended September 30, 2016 and 2015.</p></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2016Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
26800000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016Q3 cdna Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
0
cdna Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
0
CY2015Q3 cdna Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
0
cdna Collaboration Agreement Outstanding Amount
CollaborationAgreementOutstandingAmount
0
CY2016Q3 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2015Q3 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2016Q3 cdna Gain Loss On Private Placement Warrants
GainLossOnPrivatePlacementWarrants
-1386000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5150000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3489000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-23989000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8945000
CY2016Q3 cdna Private Placement Warrant Shares Using If Converted Method
PrivatePlacementWarrantSharesUsingIfConvertedMethod
382798
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1921848
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5426849
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1921848
CY2016Q2 cdna Preferred Stock Issued Shares Private Placement
PreferredStockIssuedSharesPrivatePlacement
2959300
CY2016Q2 cdna Preferred Stock Issued Shares Subsequent Financing
PreferredStockIssuedSharesSubsequentFinancing
2959300
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
948000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4957000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1357000
CY2016Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
7262000
CY2016Q2 cdna Minimum Lender Required Proceeds From Issuance Of Private Placement Offer
MinimumLenderRequiredProceedsFromIssuanceOfPrivatePlacementOffer
12000000
cdna Non Controlling Interest Investment
NonControllingInterestInvestment
634000
cdna Foreign Currency Effect
ForeignCurrencyEffect
2000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
16940000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-898000
CY2016Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
31560000
CY2016Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1077000
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
-1689000
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28794000
CY2016Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
38210000
CY2016Q3 cdna Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
1077000
cdna Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
-1689000
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2015Q4 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
0
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
529000
CY2016Q3 cdna Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
1384000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2016Q3 cdna Indefinite Lived Intangible Assets Excluding Goodwill Gross
IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
6700000
CY2016Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6244000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
237000
CY2016Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1200000
CY2015Q4 cdna Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
0
CY2016Q3 cdna Accrued Common Stock Issuance Costs Current
AccruedCommonStockIssuanceCostsCurrent
333000
CY2015Q4 cdna Accrued Common Stock Issuance Costs Current
AccruedCommonStockIssuanceCostsCurrent
0
CY2016Q3 cdna Accrued Transaction Related Fees Current
AccruedTransactionRelatedFeesCurrent
685000
CY2015Q4 cdna Accrued Transaction Related Fees Current
AccruedTransactionRelatedFeesCurrent
589000
CY2016Q3 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
302000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
662000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
89000
CY2016Q3 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
490000
CY2015Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
426000
CY2016Q3 cdna Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
293000
CY2015Q4 cdna Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
163000
CY2016Q3 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1196000
CY2015Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
756000
CY2016Q3 cdna Accrued Inventory Payable Current
AccruedInventoryPayableCurrent
324000
CY2015Q4 cdna Accrued Inventory Payable Current
AccruedInventoryPayableCurrent
0
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
300000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
258000
CY2016Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
175000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
71000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1228000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
540000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
507000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2044000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2017000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2003000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1964000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8535000
cdna Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
250000
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
344000
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
387500
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
503000
CY2016Q3 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
2000
CY2015Q3 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
8000
CY2016Q3 us-gaap Royalty Revenue
RoyaltyRevenue
98000
us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
12000
us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
41000
cdna Percentage Of Default Interest Payment
PercentageOfDefaultInterestPayment
0.0500
CY2015Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
200000
us-gaap Debt Instrument Description
DebtInstrumentDescription
The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
CY2015Q1 cdna Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
90000
us-gaap Default Longterm Debt Description Of Violation Or Event Of Default
DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
Upon the occurrence of an event of default, a default interest rate of an additional 5.00% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
CY2015Q3 us-gaap Royalty Revenue
RoyaltyRevenue
96000
us-gaap Royalty Revenue
RoyaltyRevenue
200000
us-gaap Royalty Revenue
RoyaltyRevenue
300000
CY2016Q3 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2015Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2015Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
20000000
us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
Draw A bears interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the Lender.
CY2015Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0200
us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2015-01-30
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-12-01
CY2016Q3 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
200000
CY2016Q3 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
100000
CY2015Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
100000
cdna Prepayment Penalty
PrepaymentPenalty
0.00
CY2016Q2 us-gaap Bridge Loan
BridgeLoan
18000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2900000
CY2016Q3 cdna Accrued Interest On Shareholder Loans
AccruedInterestOnShareholderLoans
700000
CY2016Q3 cdna Long Term Debt Maturities Repayments Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsRemainderOfFiscalYear
12662000
CY2016Q3 cdna Long Term Debt Maturities Repayments In Year Two
LongTermDebtMaturitiesRepaymentsInYearTwo
6984000
CY2016Q3 cdna Long Term Debt Maturities Repayments In Year Three
LongTermDebtMaturitiesRepaymentsInYearThree
6984000
CY2016Q3 cdna Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
26630000
CY2016Q3 cdna Debt Discount And Issuance Costs
DebtDiscountAndIssuanceCosts
-232000
CY2016Q3 us-gaap Long Term Debt
LongTermDebt
26398000
CY2016Q2 cdna Common Stock Purchase Price
CommonStockPurchasePrice
3.99
CY2016Q2 us-gaap Fees And Commissions Transfer Agent
FeesAndCommissionsTransferAgent
1800000
cdna Additional Issued Units
AdditionalIssuedUnits
334169
CY2016Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1700000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1002507
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.18
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.63
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
530000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
336000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1511000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1028000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M29D
CY2016Q3 cdna Income Tax Benefit Due To The Reversal Of Net Deferred Tax Liabilities
IncomeTaxBenefitDueToTheReversalOfNetDeferredTaxLiabilities
400000
cdna Income Tax Benefit Due To The Reversal Of Net Deferred Tax Liabilities
IncomeTaxBenefitDueToTheReversalOfNetDeferredTaxLiabilities
900000
CY2016Q3 cdna Intersegment Sales
IntersegmentSales
0
cdna Intersegment Sales
IntersegmentSales
0
CY2016Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1068000
CY2015Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
217000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2172000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
575000

Files In Submission

Name View Source Status
0001564590-16-029303-index-headers.html Edgar Link pending
0001564590-16-029303-index.html Edgar Link pending
0001564590-16-029303.txt Edgar Link pending
0001564590-16-029303-xbrl.zip Edgar Link pending
cdna-10q_20160930.htm Edgar Link pending
cdna-20160930.xml Edgar Link completed
cdna-20160930.xsd Edgar Link pending
cdna-20160930_cal.xml Edgar Link unprocessable
cdna-20160930_def.xml Edgar Link unprocessable
cdna-20160930_lab.xml Edgar Link unprocessable
cdna-20160930_pre.xml Edgar Link unprocessable
cdna-ex311_8.htm Edgar Link pending
cdna-ex312_7.htm Edgar Link pending
cdna-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending